Healthcare - Biotechnology - NASDAQ - US
$ 0.8284
-18 %
$ 45.7 M
Market Cap
-0.58
P/E
CASH FLOW STATEMENT
-91.5 M
OPERATING CASH FLOW
47.5 M
INVESTING CASH FLOW
41.8 M
FINANCING CASH FLOW
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Omega Therapeutics, Inc.
| Net Income | -97.4 M |
| Depreciation & Amortization | 6.77 M |
| Capital Expenditures | -2.87 M |
| Stock-Based Compensation | 8.79 M |
| Change in Working Capital | -9.37 M |
| Others | -2.65 M |
| Free Cash Flow | -94.4 M |
Cash Flow
Millions
| Dec-2023 | Dec-2022 | Dec-2021 | Dec-2020 | Dec-2019 | |
|---|---|---|---|---|---|
| OPERATING CASH FLOW | |||||
| Net Income | (97.4) | (102.7) | (68.3) | (29.4) | (17.9) |
| Depreciation & Amortization | 6.8 | 5.2 | 1.4 | 1.1 | 0.8 |
| Deferred Income Tax | 0 | 0 | 1.3 | 25 K | 3 K |
| Stock Based Compensation | 8.8 | 7.8 | 3.2 | 0.6 | 0.3 |
| Other Operating Activities | (0.3) | 1.1 | 0.1 | 59 K | 41 K |
| Change in Working Capital | (9.4) | (9.9) | 4.7 | 1.6 | 1.2 |
| Cash From Operations | (91.5) | (98.5) | (57.6) | (26.1) | (15.7) |
| INVESTING CASH FLOW | |||||
| Capital Expenditures | (2.9) | (1.4) | (1.5) | (1.8) | (0.9) |
| Other Items | 50.4 | (16.7) | (38.9) | 0 | 0 |
| Cash From Investing Activities | 47.5 | (18.1) | (40.4) | (1.8) | (0.9) |
| FINANCING CASH FLOW | |||||
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Total Debt Repaid | 1.6 | 0 | 8.0 | 0 | 4.0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0.2 | 0.7 | 122.3 | 48.6 | 8.0 |
| Cash From Financing Activities | 41.8 | 0.7 | 261.5 | 48.6 | 12.0 |
| CHANGE IN CASH | |||||
| Net Change In Cash | (2.2) | (115.9) | 163.5 | 20.7 | (4.6) |
| FREE CASH FLOW | |||||
| Free Cash Flow | (94.4) | (99.9) | (59.1) | (27.9) | (16.6) |